RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Continuous Theta Burst Stimulation of the Right Posterior Parietal Cortex for Generalized Anxiety Disorder

This randomly assigned, rater-blinded clinical trial evaluates the effectiveness, safety, and tolerability of continuous theta burst stimulation (cTBS) in adults with generalized anxiety disorder (GAD). you would be randomly assigned in a 1:1 ratio to receive cTBS targeting either the right posterior parietal cortex (R-PPC) or the right dorsolateral prefrontal cortex (R-DLPFC).

Official registry: https://clinicaltrials.gov/study/NCT07770919 · Military Hospital 175 · enrollment listed as 40

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Continuous Theta Burst Stimulation of the Right Posterior Parietal Cortex, or Continuous Theta Burst Stimulation of the Right Dorsolateral Prefrontal Cortex. The registry lists allocation as randomized. This randomly assigned, rater-blinded clinical trial evaluates the effectiveness, safety, and tolerability of continuous theta burst stimulation (cTBS) in adults with generalized anxiety disorder (GAD).

They plan to enroll about 40 people at Ho Chi Minh City. Taking part typically means using or being fitted with a device plus check-ins.

Official title (unrewritten)

A Randomized Rater-Blinded Trial Comparing Continuous Theta Burst Stimulation Targeting the Right Posterior Parietal Cortex and Right Dorsolateral Prefrontal Cortex for Generalized Anxiety Disorder

Interventions: Continuous Theta Burst Stimulation of the Right Posterior Parietal Cortex, Continuous Theta Burst Stimulation of the Right Dorsolateral Prefrontal Cortex

Primary outcome (registry wording): Change in Hamilton Anxiety Rating Scale (HAM-A) Total Score

Who it is for (from inclusion criteria)

Ages 18 Years to 65 Years
Age 18 to 65 years
Diagnosis of generalized anxiety disorder (GAD) according to ICD-10 criteria (F41.1), confirmed by a psychiatrist
GAD must be the primary diagnosis and the main reason for treatment at the time of enrollment. Current or past comorbid major depressive disorder will be identified and recorded
Hamilton Anxiety Rating Scale (HAM-A) total score \>18 at screening/baseline

Who the registry excludes

Intracranial or head/neck metallic foreign bodies or implants that constitute a contraindication to TMS or MRI
Implanted electronic devices such as a cardiac pacemaker, implantable cardioverter-defibrillator, or deep brain stimulator
Untreated or clinically unstable thyroid dysfunction based on abnormal TSH and/or free T4 levels
Clinically significant intracranial structural abnormalities that may affect TMS safety, neuropsychiatric presentation, or study neurophysiological measures
History of epilepsy or seizures, except febrile seizures in childhood
Other major psychiatric disorders, including schizophrenia, delusional disorder, or eating disorders
Acute suicide risk, including clear suicidal ideation or behavior

Public study contact (from the registry)

Dang Minh Ly, MD

+84359999741

drminhdang@outlook.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Military Hospital 175 — Ho Chi Minh City, Vietnam (recruiting)

Related recruiting trials in this snapshot

RecruitingPhase 2Bethesda, Maryland

Phase 2: testing Fluoxetine for Anxiety Disorders

Study Description: This study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M/EEG).

NCT00018057 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

RecruitingNot a traditional drug phaseRichmond, Virginia

Not a traditional drug phase: Antioxidant for Peripheral Vascular Diseases

The purpose of this research study is to examine the role oxidants, substances produced in the blood that can damage blood vessel function, may play in blood vessel function in healthy individuals as well as individuals with mental health disorders (posttraumatic stress disorder (PTSD) and/or generalized anxiety disorder (GAD)).

NCT04916327 · Official ClinicalTrials.gov record · Virginia Commonwealth University

RecruitingNot a traditional drug phaseLos Angeles, California

Not a traditional drug phase: Deep Brain Stimulation for Fear

Anxiety disorders such as post-traumatic stress disorder (PTSD) and generalized anxiety disorder (GAD) affect a large number of individuals with a significant portion of patients failing to improve with current treatments. this study wants to understand the brain mechanisms that produce fear and anxiety in humans.

NCT05120635 · Official ClinicalTrials.gov record · Duke University

FAQ about this NCT record

Is NCT07770919 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07770919?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07770919?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary